Abstract ND06: ECI830, a potent and highly selective CDK2 inhibitor, for the treatment of HR+/HER2− breast cancer and <i>CCNE1</i> -amplified tumors
Samuel Ho(American Institutes for Research), Vivek Rauniyar(University of California, Berkeley), Sajan Joseph(Eli Lilly (United States)), Ophélia Maertens(American Institutes for Research), Imad Hanna(Novartis (Switzerland)), Anna Uvarova(American Institutes for Research), Bradley French(American Institutes for Research), Neil Umbreit(American Institutes for Research), Ying Huang(American Institutes for Research), Eric Fang(American Institutes for Research), Fallon Lin(Novartis (United States))
Cited by 0
Related Papers
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
|Cell|2015|377
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
|Cancer Discovery|2012|297
Enantioselective Halocyclization Using Reagents Tailored for Chiral Anion Phase-Transfer Catalysis
|Journal of the American Chemical Society|2012|265
Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
|Cancer Cell|2011|259
Elucidating Distinct Roles for <i>NF1</i> in Melanomagenesis
|Cancer Discovery|2012|250